Literature DB >> 15846190

Should we offer expectant management in cases of severe preterm preeclampsia with fetal growth restriction?

Roberta M Shear1, Denyse Rinfret, Line Leduc.   

Abstract

OBJECTIVE: The purpose of this study was to assess maternal and fetal morbidity and death in cases of severe preterm preeclampsia that were managed expectantly. STUDY
DESIGN: It is a retrospective study that included 155 singleton pregnancies with severe preeclampsia at <34 weeks of gestation that were managed expectantly over a 10-year period. Perinatal outcomes of both mother and fetus were stratified according to gestational age and the severity of fetal growth restriction < or =3th percentile, 4th to 5th percentile, >5th to10th percentile, and >10th percentile.
RESULTS: The mean gestational age at admission was 30.2 +/- 2.4 weeks (range, 23.9-34.0 weeks). The mean latency period was 5.3 +/- 5.2 days, with a perinatal mortality rate of 3.9%. Gestational age of <30 weeks of gestation was the strongest variable that affected perinatal outcome, whereas fetal growth restriction played a marginal role.
CONCLUSION: Expectant management is recommended strongly in fetuses at <30 weeks of gestation, irrespective of fetal growth restriction. Delivery should be considered at >30 weeks of gestation.

Entities:  

Mesh:

Year:  2005        PMID: 15846190     DOI: 10.1016/j.ajog.2004.10.621

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  An analysis of expectant management in women with early-onset preeclampsia in China.

Authors:  Q Chen; F Shen; Y F Gao; M Zhao
Journal:  J Hum Hypertens       Date:  2014-10-23       Impact factor: 3.012

2.  Impact of fetal growth on pregnancy outcomes in women with severe preeclampsia.

Authors:  Ebony B Carter; Shayna N Conner; Alison G Cahill; Roxane Rampersad; George A Macones; Methodius G Tuuli
Journal:  Pregnancy Hypertens       Date:  2017-02-17       Impact factor: 2.899

3.  The expression of pentraxin 3 and tumor necrosis factor-alpha is increased in preeclamptic placental tissue and maternal serum.

Authors:  Ping Zhou; Xin Luo; Hong-Bo Qi; Wen-Jun Zong; Hua Zhang; Dan-Dan Liu; Qing-Shu Li
Journal:  Inflamm Res       Date:  2012-06-20       Impact factor: 4.575

4.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

5.  Adverse maternal and neonatal outcomes among women with preeclampsia with severe features <34 weeks gestation with versus without comorbidity.

Authors:  Kartik K Venkatesh; Robert A Strauss; Daniel J Westreich; John M Thorp; David M Stamilio; Katherine L Grantz
Journal:  Pregnancy Hypertens       Date:  2020-03-10       Impact factor: 2.899

6.  Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study.

Authors:  Jane Weiler; Stephen Tong; Kirsten R Palmer
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.